MLV & Co. Initiates SciClone Pharmaceuticals At Buy

by Monica Gerson, Benzinga Staff Writer
June 29, 2015 10:14 AM | 20 seconds read |
Analysts at MLV & Co. initiated coverage on SciClone Pharmaceuticals, Inc. SCLN with a Buy rating. The target price for SciClone Pharmaceuticals is set to $15. SciClone Pharmaceuticals shares have gained 78.29 percent over the past 52 weeks, while the S&P 500 index has surged 7.17 percent in the same period. SciClone Pharmaceuticals' shares fell 0.21 percent to close at $9.36 on Friday.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: InitiationAnalyst RatingsMLV & Co.
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!